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CELIAC DISEASE
Abstract

New research has revealed that Celiac disease, an autoimmune illness affecting the small
intestine, has more ties with neurological side effects than once was thought. The classic
and most well known presentation of Celiac disease is gastrointestinal, including
symptoms such as abdominal pains, nausea, diarrhea, and flatulence. Researchers have
more recently found a correlation between Celiac disease and neurological illnesses such
as epilepsy, depression, dementia, and ADHD. Physician awareness of the disease and
the neurological side of the illness should be heightened in order for patients to receive
earlier diagnosis and a better quality of life. Because of the difficulty to diagnose this
disease when the presentation is neurological, there is indication for mass screening
programs to be implemented.
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There is a growing awareness of gluten-intolerances and an increased number of
people switching to a gluten-free diet and life-style. Package Facts reported a 30% rise
in gluten-free products bought in the US between 2006 and 2010 (Case, 2012).
Consumers have found that grocery stores and restaurants are starting to stock gluten-free
options. Many of those who are making this switch are doing so because of a disorder
called celiac disease (CD) (Case, 2012).
However, because of varying symptoms of the disease and the lack of knowledge
by physicians, CD is still under-diagnosed. Dr. Peter H.R. Green stated at the 2008
meeting of The American Academy of Allergy, Asthma, and Immunology that it is
estimated that 1% of the population of the US have CD, but only 3% of those with the
disease have been diagnosed (Brunk, 2008). Large proportions of those who have the
disease are not diagnosed until adulthood (Rubio-Tapia & Murray, 2010). One of the
reasons so many are not being diagnosed early is because the disease is being masked by
symptoms that seem to be unrelated to a gastrointestinal disease. Many of those with CD
have neurological symptoms that look strikingly like other disorders or diseases. It has
been estimated that between 6-10% of those with CD present with neurological
symptoms (Alehan, Ozçay, Eroi, Canan, Cemil, 2008).
Sadly, many physicians and patients are unaware of the variety of presentations of
CD presents, which results in misdiagnosis (Zelnik, Pacht, Obeid, Lerner, 2004). Some
patients struggle for years with symptoms that respond poorly to an unrelated treatment
plan. Mass screenings could be a way that the United States can rectify the estimated
97% of those who go undiagnosed. These screenings are cost effective and can help
lower mortality rates (Brunk, 2008).
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Pathophysiology
CD is an autoimmune disease that could potentially affect every system of the

body. Those with CD have leaky intercellular tight junctions in the small intestine, which
cause gluten, rye, and barley proteins to leak into the lamina propria (Zawahir, Safta,
Fasano, 2009). This stimulates an inflammatory response caused by the innate immune
system response creating proinflammatory cytokines. Because of the inflammation there
is cell damage and these lysed cells produce transglutaminase 2 (TG2). TG2 is a protein
that assists with angiogenesis, the process of formation of blood vessels from preexisting
blood vessels (Gilbert, 2000). Immunoglobulin-A (IgA) that is specific to the patient is
produced in response to the abnormal levels of TG2 (Zawahir & et. al, 2009). The
antibody IgA then attacks TG2 (Myrsky, Kaukinen, Syrjänen, Korponay-Szabó, Mäki, &
Lindfors, 2008). When angiogenesis is inhibited by the antibody formation, there is no
sprouting of new endothelial cells, migration of mesenchymal cells from connective
tissue, or maturation of the new blood vessels (Gilbert, 2000). This decrease in blood
flow to the tissues causes the mucosa on the small intestine to become severely damaged
due to the missing capillary beds (Myrsky & et al., 2008).
When seen in an endoscopy, the microvilli and folds in the intestine appear
flattened, atrophied, scalloped, lesioned, and/or fissured (Zawahi & et al., 2009).
Because the microvilli are responsible for the absorption of nutrients, those with
untreated CD lack the ability to absorb many of the nutrients needed for daily life,
causing multiple systems in the body to be affected (Ryan & Grossman, 2010). Because
CD can cause damage throughout the body, there are not only gastrointestinal symptoms,
such as diarrhea, abdominal pain, and weight loss, but also problems in the

6

CELIAC DISEASE
musculoskeletal system, neurological system, and integumentary system (Ryan & et al.,
2010).
The lack of nutrients is not the only cause of multiple systems being affected by
gluten. Researchers in Finland have found that there are antibody deposits in hepatic
blood vessels, which can cause mild liver abnormalities (Myrsky & et al., 2008). Those

with neurological symptoms have also been found to have antibodies in the brain vessels.
This causes neuroblast apoptosis, gluten ataxia, and other neurological disorders (Myrsky
& et al., 2008).
Genetics and Possible Causes
There is a heavy link between CD and genetics. CD is linked to the alleles HLA
(Human Leukocyte Antigen)-DQ2 or HLA-DQ8 (Ryan & et al., 2011). Those with CD
have more than a 90% chance of having a genetic expression of HLA-DQ2.
Monozygotic twin studies have shown that there is a 83-86% likelihood that if one twin
has the disease, the other will as well (Wolters & Wijmenga, 2008). A person with the
disease has a 5-15% likelihood that another family member will also have CD. There is
also higher prevalence of CD in different ethnicities and geographical locations. For
example, there are a high number of people in northern Europe with CD (King &
Ciclitira, 2000); many in the Middle East, India, and North Africa have also been
diagnosed at higher rates than the rest of the world (Zawahir & et al., 2009). The reason
for this has been highly studied; and most likely it is because of genetic variances and
tendencies in ethnic groups and families (Zawahir & et al., 2009).
A Swedish study investigated the potential for cultural causes. In the mid-1980s,
there was a 300% increase in children less than two-years-old being diagnosed with CD
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(Wolters & et al., 2008). This was related to changing the recommendations for when

gluten was introduced to the infant. It was previously four months, but they changed the
recommendation to six months. This caused infants to be exposed to gluten without
breastfeeding simultaneously. The government changed the recommendation back to
four months for gluten introduction, while also breastfeeding. As a result, CD diagnosis
of children dropped. There was also a thought in Sweden that because children born in
the summer had a higher likelihood of being diagnosed with CD, infections in the winter
when gluten was introduced could be the cause. This has not been proven, but merely
speculated. In addition, there have been correlations between human intestinal
adenovirus and rotavirus infections and higher CD diagnosis. However, the propositions
that cold winters with higher infection rates or cultural introduction to gluten at a later
age is the cause of higher CD diagnoses is doubtful, especially because there is also a
high incidence in the disease in many different cultures and climates (Wolters & et al.,
2008).
Diagnosis
There are many markers in the body that lead health care providers to a diagnosis
of CD and some markers are more diagnostic than others. The various pathologies of the
disease are the cause of these markers (Ryan & et al., 2011). The inflammatory response
in the intestine causes the microvilli to flatten and atrophy. Antibodies are made against
the gluten proteins. Many with CD also have a genetic factor predisposing them to the
disease. Because of these processes, there are various tests that can be done to diagnosis a
person with the disease (Ryan & et al., 2011).
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It was once thought that a biopsy of the small intestine was the gold standard for
testing CD (Hill & et al., 2008). A biopsy is usually encouraged or scheduled after a
positive serum test. However, research has shown that serum tests (used to test various
antibodies in the blood) are just as effective and demonstrative as biopsies and therefore
many can be spared the discomfort biopsies bring. The antibodies created by those with
CD, exposed to gluten are IGA and IgG antigliadin-antibodies (AGA-IgA), TGA, and
antiendomysium antibodies (EMA), and HLA-DQ typing (Hadithi & et al., 2007).
Recent studies have shown that tTGA levels in the blood is the most accurate at
diagnosing CD (Hill & et al., 2008). First-generation assays to test for tTGA were not as
accurate as other tests, but second-generation assays have started using human purified or
human recombinant tissue transglutaminase-2 and have become much more sensitive and
accurate (Hill & et al., 2008).
The biopsy can be tested for specific antigens on the intestine using
immunohistochemistry (Ramos-Vara, 2005). Biopsies have been considered beneficial
because of the visibility of damage to the intestines. However, there are problems with
them. First, biopsies can show the atrophy and lesions in the intestines, but CD is not the
only disease process that causes lesions and atrophy (Ramos-Vara, 2005). Second, even
though this antigen testing can be accurate, many laboratories in the U.S. do not have this
kind of technology (Hill & Holmes, 2008). Another issue with biopsies is that of
compliance. After a positive serum test, patients usually are prescribed a gluten-free diet.
The study Hill and Holmes conducted also discovered that it takes from 6-319 days for a
biopsy to be performed due to physicians and patients schedules. This means, many have
been on a gluten-free diet for a length of time. The diet change almost always causes the
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negative symptoms to resolve in the patients. However, in order for the biopsy to

confirm a patient positive with CD, the patient will have to maintain a gluten diet in order
for the gluten to have a diagnostic effect. This causes many to be hesitant about having
the biopsy performed, due the return of their negative symptoms from CD or the worry of
added damage to the intestines because of the ingestion of gluten (Hill, et al., 2008).
Because the disease is linked to specific alleles, genetic testing results in almost a
100% accurate diagnosis (Rashtak & Murray, 2007). This test also has benefits for those
who wish to be tested for CD but are already on a gluten-free diet and do not wish to
resume a gluten diet in order to receive an accurate biopsy or antibody test. The genetic
allele is always present in CD patients, whatever diet they are on. However, there are
drawbacks to the genetic testing. Genetic testing, no matter what is being tested, should
be regarded with delicacy due to the familial issues it can bring up and the sensitivity it
has. Genetic counselors should be available if the patient requests (Rashtak & et al.,
2007).
Clinical Manifestations
Many believe that because CD is a gastrointestinal disease, the only symptoms
associated with this disease are gastrointestinal; this belief is false. The symptoms are
wide spread and multisystem (Thom, Longo, Running, & Ashley, 2009). Because of this,
CD is often attributed to other disease processes, such as liver disease, epilepsy, eczema,
anemia, fatigue, and osteoporosis. Since these symptoms are often isolated disease
processes in some cases, CD is many times attributed to these solitary disorders and CD
sometimes overlooked as the culprit for the problems the patient is experiencing (Thom
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& et al., 2009). It has been estimated that 7% of the time, the extragastric disorders, such
as epilepsy, ataxia, and depression are diagnosed before CD (Gobbi, 2005).
Many who are diagnosed with CD have side effects that are neurological instead
of, or alongside of, gastrointestinal symptoms. A study done by a group of doctors in
Israel researched the association of neurological disorders with CD (Zelnik & et al.,
2004). It was found that those with CD had neurological disorders such as hypertonia,
migraines, and headaches, 51% of the time and those without CD had a 19.9% chance of
having a neurological disorder. Many of these neurological disorders were mitigated by a
gluten-free diet (Zelnik & et al., 2004). Other studies have researched the prevalence of
CD in those with neurological disorders and have had similar results (Salur & et al.,
2000).
Ataxia
The inflammatory response in the intestines that occurs with gluten ingestion in a
person with CD triggers the release of AGA as well as anti-TGase2 (Boscolo & et al.,
2007). Those who suffer from idiopathic ataxia and have AGA antibodies in their system
are diagnosed with “gluten ataxia” (GA) as opposed to the idiopathic familial ataxia
unrelated to gluten and AGA (Boscolo & et al., 2007).
The manifestation of GA in CD patients is fairly common. Results vary on the
percentage of those with ataxia who have AGA. A study performed on 224 patients with
idiopathic ataxia discovered that 41% of the population had AGA, while only 13% had
familial ataxia (Hadjivassiliou & et al., 2003). Another study found 10.6% of those in
the idiopathic ataxia population with GA, while another study presented with 17.7% of
the population (Boscolo & et al., 2007). However, one study has shown there to be no
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GA patients in the population of idiopathic ataxia of 32. Because of studies like these,
there is a controversy on whether or not AGA is indeed a cause of ataxia. This
controversy is common in most studies seeking to relate CD with other neurological
disorders (Boscolo & et al., 2007).
An interesting study in Italy researched the affects of the AGA and anti-TGase2
antibodies on mice (Boscolo & et al., 2007). Researchers injected the antibodies into the
central nervous systems of the mice. The injection caused ataxia in all the mice and
researchers believe it is possible to suspect that the antibodies produced in those with CD
could interact with the blood-brain barrier and cause altered permeability. This
permeability of the blood-brain barrier could allow for an increase in likelihood for
neurological disorders, such as ataxia. Other studies have shown that those with GA have
anti-TGase2 antibodies on the brain vessels themselves. The immune response in the
central nervous system could be causing damage to the neurons and therefore causing
ataxia with those with CD (Boscolo & et al., 2007).
Because the circulating antibodies are the cause of the damage to the central
nervous system, causing ataxia in patients, it is logical to assume that when a patient with
CD adheres to a gluten-free diet, leading to a cessation in antibody formation, then the
ataxia will resolve. A study done in the UK sought to prove this in an experimental
setting (Hadjivassiliou, Davies-Jones, Sanders, Grunewald, 2003). There were 40
patients selected with gluten ataxia and 26 of them were placed on a strict gluten-free
diet. Strict adherence to the diet is necessary, to see results from diet change. The
remaining 14 patients refused the diet change. Both groups had similar baseline ataxia
symptoms. Those with the gluten-free diet had a significant improvement in their
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symptoms and it was concluded that a gluten-free diet was sufficient treatment for most
cases of GA (Hadjivassiliou, Davies-Jones & et al., 2003). However, if after a year of a
strict gluten-free diet and there has been no change in the ataxia, an immunosuppressant
or intravenous immunoglobulin may be used (Hadjivassiliou, David, Woodroofe,
Williamson, Richard, 2008).
Autism
Autism is a social and mental disorder that affects 1 out of 150 children in the
United States, according to a study in 2002 (Genius & Bouchard, 2009). This is a
chronic disorder with no known cure and the prognosis of autism is very grim. It is
estimated that 85% of the outcomes are not favorable to the patient and families. The
disorder manifests as difficulty in socialization and communication, a selection and
obsession with just a few interests, and stereotyped behaviors. Some manifest with
aggression, irritability, self-injury, and hyperactivity (Genius & et al., 2009).
In a case study performed by Dr. Stephen Genius, he studied a 5-year-old boy
who was diagnosed with severe autism disorder (Genius & et al., 2009). He had severe
communication and socialization difficulties, would experience sensory processing delay,
had marked language delay, experienced fatigue, confusion, could not tolerate bright
lights and experience ringing in his ears to the point that he would constantly have his
fingers in his ears. He also had bloating and abdominal pain with nausea, vomiting, and
diarrhea. He had many tests performed in order to see if any treatments could be done to
assist with his diagnosis. It was found that he had deficiencies in fat-soluble vitamins (A,
D, E), coenzyme Q10, and folate. His anti-TG2ase and EMA levels were extremely high
at over 450 times the normal levels. Because these levels are sometimes indicative for
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CD, he was place on a gluten-free diet as well as an increase in the nutrients he was
missing in his body. In one month, his gastrointestinal symptoms were gone and his
autistic behavior was significantly decreased. He was also able to communicate at a
much higher level than previously. In three months, he was able to go back to his normal
school classroom with no aides or special education. In a follow up 2 ½ years later, he is
still doing “incredibly well”, his mother says (Genius & et al., 2009).
As successful as this story is, there have been many experimental studies
performed with negative findings. A study with 120 patients with CD had no findings of
autism in the population and a study of 11 patients with autism found no CD in the
population (Pavone, Fiumara, Bottaro, Mazzone, Coleman, 1997). These populations
however may have been too small to have any stiistical significance (Pavone & et al.,
1997).
A study performed retrospectively chose 150 random children with autism,
pervasive developmental disorder (not otherwise specified), childhood disintegrative
disorder, and Asperger disorder (Barcia, Posar, Santucci, Parmeggiani, 2008). They were
all tested for CD and five out of 150 or 3.33% of the children were diagnosed with CD. In
general, the pediatric population has a 1 out of 106 or 0.94% chance of having CD.
Those performing this study and also those who performed the case study discussed
earlier (Genius & Bouchard, 2009) both recommend screening all children with autism
for CD. If they test positive, they should have gluten restricted in their diet and any
nutrients that are diminished should be replaced (Barcia & et al., 2008).
Another study took a population of only ten autistic children and increased their
folate, fatty acids, cod live oil, and coenzyme Q10 (Patel & Curtis, 2007). They did this
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because findings have shown that those with autism sometimes have these nutritional
deficiencies. The study also added behavioral therapy to the treatment and decreased any
risk of heavy metal exposure. The results were extremely positive. All ten children
improved their autistic symptoms. Since correcting a potential nutritional deficiency
treated the autism, it is logical to link those with nutritional deficits who also have autistic
symptoms to CD, since CD causes decreased nutrient absorption. This study should push
others to further research this issue (Patel & et al., 2007).
There has also been research done with placing all those with autism on a glutenfree diet without knowledge of CD. In a single blind study, researchers randomly
assigned half to a gluten-free and casein-free diet and the others to a regular diet
(Knivsburg, Reichelt, Hoien, Nodland, 2002). Those placed on the special diet had
improvment in the areas of the autistic-spectrum (Knivsburg & et al., 2002).

Epilepsy
The issue of CD being associated with epilepsy is much debated. Some studies
have found that the prevalence of epilepsy with those diagnosed with CD is merely 1%
while others claim 21.5% (Barera, Mora, & Parma, 2008). There are many reasons for
these discrepancies, including type and location of seizures seen. Occipital epilepsy is
generally highly associated with CD (Gobbi, 2005). Another study found that 9% of
patients with occipital epilepsy had CD from a 72 patient population with epilepsy. Of
the patients studied with epilepsy from centrotemporal spikes, none had CD (Gobbi,
2005).

CELIAC DISEASE

15

As CD goes untreated, there is a higher likelihood for cerebral calcifications that
are usually located in the occipital region of the brain in patients with CD (Gobbi, 2005).
Cerebral calcifications are associated with epilepsy. An Italian study performed in 1997
recorded many cases of patients with epilepsy and cerebral calcifications seen on a CT
scan. It is thought that silent or latent CD that goes too long untreated could affect
patients by causing cerebral calcifications and epilepsy. Another study reported that
those with CD who had an average of 5.9 years before diagnosis and treatment of CD,
there was a 0.79% likelihood of them presenting with epilepsy and cerebral calcifications.
However, after an average of 10 years before diagnosis and treatment of CD, there was a
3.5% likelihood of epilepsy and a 1.7% likelihood of cerebral calcifications. While this
study just shows a correlation and does not prove definitively of any direct causes of CD,
it shows a strong link between the age of diagnosis and treatment and possible damage to
the neurological system (Gobbi, 2005).
There is much discussion on why there seems to be a higher amount of
calcification and seizure activity in the occipital region of the brain. Some have
speculated that it is an autoimmune inflammatory response, similarly seen in other
neurological disorders associated with CD, such as ataxia (Licchetta, Bisulli, Vito,
Morgia, Naldi, Volta & et al., 2011). Chronic inflammation caused by the immune
response can increase calcium deposits, leading to the calcification of the occipital lobe.
However, there are other disease processes that present with cerebral calcifications and
are not autoimmune related, an example being Sturge-Weber syndrome. Others say both
the calcification and the epilepsy could be caused by vascular abnormalities, caused by
the autoimmune response, which then leads to deterioration of the blood brain barrier.
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However, some suggest that the calcifications are formed after the seizure occurs. A
patient in a case study at the University of Bologna had an excision of a calcified lesion,
yet still had episodes of seizing. There is still much research that needs to be done before
there is a better understanding between the relationship of CD, cerebral calcifications,
and epilepsy (Licchetta & et al., 2011).
Depression
A meta-analysis performed in 2011 reviewed 18 studies on depression and CD
(Smith, 2012). This analysis has shown that there are more accounts of depression in CD
adult populations than in healthy adult populations. Not only is depression more
prevalent in CD patients, but also it is commonly more severe in those with CD than
those who are healthy. However, based on the studies, there was not much difference in
the prevalence of depression in patients with CD and those with other chronic illnesses.
This might lead to the belief that the depression is due to a more difficult lifestyle and
disabilities caused by CD rather than any pathological cause of depression from CD.
This belief is also supported by the fact that when a patient diagnosed with CD and
depression starts a gluten-free diet, there is often little change in their depression. There
is also not a correlation between CD and anxiety, another emotional disorder that is
commonly associated with depression. This could also be because there might not be a
pathological relationship with emotional disorders and CD. However, there are some
who believe that depression is caused by the autoimmune response in the body that could
damage the nervous system. Depression could also be caused by the low amounts of
nutrients the body has available, due to the damage in the small intestine. There is still
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much room for research this area. Many of the studies performed have only been
questionnaires and do not include experimental data (Smith, 2012).
Schizophrenia
Similar to many other psychiatric disorders, the cause of schizophrenia is vaguely
understood. Because of this hazy understanding, there have been various studies to seek
if a link between schizophrenia and CD exists (Kalaydjian, Eaton, Cascella, Fasano,
2006). Some studies have confirmed a possible link, while other studies deny such
association (Kalaydjian, Eaton, Cascella, Fasano, 2006).
A literature review in 2006 claimed that it was beneficial for those with
schizophrenia to be screened for CD due to the high prevalence of those with the mental
disorder to also have CD (Kalaydjian, Eaton, Cascella, Fasano, 2006). While it is unclear
what the association between the two diseases is, some studies have found that some
schizophrenics have found it beneficial to their symptoms to adhere to a gluten-free diet.
The hypothesized reason for the higher incidence of CD in schizophrenia is that the
antibodies interact with various chemicals in the brain, causing the psychiatric symptoms.
Another hypothesis stems from the fact that it has been found that those with
schizophrenia have a higher reported amount of opioid peptides that form exorphine,
which can cross the blood-brain barrier and activate the region of the brain that is
associated with schizophrenia. Studies have shown that schizophrenia patients that have
these peptides removed using dialysis have a reduction in their symptoms. These
peptides are seen in high amounts in gluten and casein foods. This may be why, when
patients eat only gluten-free and casein free foods, their symptoms decrease (Kalaydjian
& et al., 2006).

CELIAC DISEASE

18

One study in Maryland researched many different areas across the country and
tested over 2,300 participants (Cascella & et al., 2011). In this study, 1,401 participants
were clinically diagnosed with schizophrenia, while 900 participants had never been
diagnosed with schizophrenia and consisted of the control group. Of those with
schizophrenia, 23.1% had moderate to high levels of AGA and 5.4% of this population
had moderate to high levels of tTGA in their blood. Only 3.1% of the control sample had
moderate to high levels of AGA and 0.80% had moderate to high levels of tTGA
(Cascella & et al., 2011). Other older studies found similar results as Cascella’s study
(Reichelt & Landmark, 1995).
In spite of this, not all researchers are in one accord. For example, study at John
Hopkins found similar findings as the Cacella’s study, however, this study claimed that
the antibodies (IgG and IgA) found in greater percentages with the schizophrenic patients
were different from those found in CD patients (Dickerson & et al., 2010). The
antibodies in the CD patients are specific IgG antibodies to deaminated gliadin and IgA
antibodies to GTGA, both of which were not found in higher numbers in the
schizophrenic group. To summarize, this study claims those antibodies are different in
schizophrenics and CD patients, which could lead to the conclusion that the etiology of
schizophrenia is unrelated to CD (Dickerson & et al., 2010).
This leads to the question of whether the previous studies on schizophrenia and
CD had extensively studied the specific sub-types of antibodies in order to be sure they
were the ones diagnostic for CD. There is room for further study in the way of testing
those with schizophrenia specifically for the genetic allele responsible for CD and also
testing using the biopsy test (Dickerson & et al., 2010). This would better indicate
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exactly how many patients with schizophrenia are clinically diagnosed with CD as
opposed to the general population (Dickerson & et al., 2010).
Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADHD) is a behavioral and psychiatric
disorder that affects over 5% of children worldwide (Güngör, Celiloglu, Özcan, Raif,
Selimoglu, 2013). Like other neurological disorders, results have been varied on the
association. An Italian study tested 78 patients from age 3-57 with untreated CD
(Niederhofer & Pittschieler, 2006). All 78 patients were assessed for ADHD symptoms.
It was found that there were markedly more with ADHD symptoms in this CD sample
than the worldwide average. These patients were then placed on a gluten-free diet. After
six months, the patients and/or their caregivers reported that the ADHD behaviors were
overwhelmingly decreased. Of those studied, 74% wished to continue on a gluten-free
diet even after the study had been completed (Niederhofer & et al., 2006).
A study by pediatric physicians screened those with untreated CD for various
psychiatric disorders, including ADHD, as well as screening a control group without CD
for the same disorders (Zelnik, Pacht, Obeid, Lerner, 2004). It was found that over 20%
of those with CD confirmed positive for ADHD, while only 10% of the control group
confirmed positive (Zelnik & et al., 2004).
Like many research topics, the research is conflicting. A study in 2012 found that
of the 362 ADHD children tested for CD, only four (1.1%) were confirmed positive for
tTGA and only one (0.27%) was confirmed positive with the biopsy testing (Güngör,
Celiloglu, Özcan, Raif, Selimoglu, 2013). In the control group of non-ADHD children
tested for CD, three (0.8%) were confirmed positive for CD. These results are not
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statistically significant to conclude there is an association between ADHD and CD.
Because of these varied reports, there is room for more research to be done (Güngör & et
al., 2013).
Migraines
Migraines have been a mysterious phenomenon that has plagued many in the
world and seem to have an elusive cause. While many cannot find relief, researchers
have been busy seeking out connections. There have been a few studies recently that
have seen a possible association between migraines and CD.
A study in Turkey by Alehan, Ozçay, Eroi, Canan, and Cemil (2008) researched
children with migraine headaches. The study took 73 children with migraines and a
control group of 147 children with minor respiratory illnesses. The control group
children had no history of migraine headaches or gastrointestinal problems. The
researchers tested each group for tTGA antibodies and IgA. Those who had positive
antibodies, were asked to receive a biopsy in order to most effectively diagnose for CD.
Four children (5.5%) in the study group were found to have positive tTGA antibodies,
while only one patient (0.6%) in the control group had positive tTGA antibody test
results. Three of the positively tested children were biopsy tested and showed that there
could be potential for CD. All the positively tested children had an MRI and one of the
children showed some white matter in the subcortex, which could be a lesion due to CD
(Alehan & et al., 2008).
While this study has shown a substantial correlation between migraines and CD in
children, there is another similar study that has shown no correlation between children
with CD and migraines (Lehat, Broide, Leshem, Evans, Scapa, 2000). The study tested
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the patients for both IgG antibodies and IgA. Of a study group with neurological
dysfunctions, 13% tested positive for IgG antibodies and only 9% of the control group
tested positive for the antibodies. However none of the patients in either group tested
positive for IgA. This study claimed that this proves there is no need to further test for
CD because the diagnostic test for CD is IgA antibodies. However, the study did not
have as large of a sample size and was researching many different neurological
symptoms and not just migraines specifically. While it was previously believed that
elevated IgA antibodies was the only positive way to test for the disease, it has now been
shown that testing for IgG antibodies can be more diagnostic for CD than testing for IgA
antibodies (Hill & Holmes, 2008). Due to more recent findings on the diagnosis of CD,
this study could in fact prove the link to CD in children with neurological disorders and
migraines (Lehat & et al., 2000).
While these studies were exclusively performed on children, there are other
studies reporting higher incidences of migraines among CD adult patients. Columbia
University surveyed 324 patients with CD, inflammatory bowel disease (IBD), and gluten
sensitivity (Dimitrova, Ungaro, Lebwohl, Green, Babyatsky, Green, 2012). There were
178 control patients who did not have any intestinal diseases or were not gluten-sensitive.
The findings resulted in 30% of the CD patients reporting chronic headaches, 56% of
those with a gluten sensitivity reporting chronic headaches, and 23% of those with IBD
experiencing headaches. However, only 14% of those in the control group reported
chronic headaches. This study also asked the participants if a gluten-free diet decreased
the severity of the migraines. Most of the responders confirmed that before a gluten-free
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diet the headaches were much worse. There is room for more research to test adults with
migraines for CD (Dimitrova & et al., 2012).
Dementia
Due to the novelty of CD research and the commonality of misdiagnosis, there are
a growing number of older adults over 60 years of age that are under diagnosed for CD
(Lurie, Landau, Pfeffer, Oren, 2008). A retrospective study in Israel looked at seven
patients diagnosed with CD after age 60. Of the seven, three also had neurological
diagnoses along with CD. One had peripheral neuropathy and the two others had longterm cognitive decline. This decline was supposed to be related to Alzheimer dementia.
After these patients were diagnosed with CD, they were placed on a gluten-free diet.
This diet change completely resolved the symptoms of the peripheral neuropathy
experienced by the first patient. The two with cognitive decline had complete reversals
of the decline after adhering to a gluten-free diet. This response to a gluten-free diet
could potentially be helpful for many who are hopelessly diagnosed with the dreaded
Alzheimer’s disease or dementia (Lurie & et al., 2008).
Another study in Italy found that an elderly population of 60 had an average time
between symptoms starting and time of diagnosis of 17 years (Gasbarrini, Ciccocioppo,
De Vitis, Corazza, 2001). The range was 0-58 years. Out of the 60 patients, 25 patients
were over the age of 65 before they were diagnosed and 8.33% of the 60 had neurological
disorders, including dementia, epilepsy, chorea, and Parkinson’s disease. Most of these
symptoms were resolved with a gluten-free diet. The percentage of those diagnosed with
CD after age 70 from the CD population has increased from 4% in the 1960s to 27% in
the 1980s. This is most likely from the increase in knowledge and screening for CD in
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the recent years, or it could be an increase in the disease itself (Gasbarrini & et al., 2001).
There has been little research done in the elderly populations to seek more understanding
on CD and dementia, however these case studies, as well as others (Desplat-Jero,
Bernard, Bagneres, Frances, 2003) and reports of the possible link are present.

Awareness
Many of the elderly in the previously mentioned study reported that the symptoms
they had were life long and were quickly resolved by a gluten-free diet (Lurie & et al.,
2008). These symptoms not only included the neurological disorders, but also
osteoporosis, liver disorders, weight loss, iron deficiency anemia, and diarrhea. While
there is joy in their new quality of life, there is also sadness that it took these men and
women 60 years to find resolution to these very treatable symptoms. It is cases like these
that reveal an extreme under awareness of CD and a need for a greater knowledge and
teaching in order to prevent patients from living with their symptoms for a prolonged
amount of time (Lurie & et al., 2008).
A study conducted by the Harbor-UCLA Medical Center, the West Los Angeles
Veterans Administration Hospital, and the Celiac Disease Foundation investigated how
much physicians in the United States knew about CD, as well as when and how those
with CD are diagnosed (Zipser & et al., 2005). It was found that primary care physicians
diagnosed only 11% of 2,440 patients with CD, while gastroenterologists diagnosed the
majority. Patients who were diagnosed by a gastroenterologist usually had been
symptomatic for an average of seven years. Those who were diagnosed by a primary
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care physician were symptomatic for less than a year before diagnosis. Only 35% of the
primary care physicians reported they had ever diagnosed a patient with CD in the
average of 20 years they had been practicing. The results of this study can lead to the
conclusion that primary care physicians who are more trained in knowing the symptoms
of CD and how to diagnose could be preventing under-diagnosis of the disease and years
of patients’ suffering with the symptoms (Zipser & et al., 2005).
The disease is also under-diagnosed because many see CD as more rare than it
actually is. CD is primarily a European disease and because America has a large number
of European immigrants, it is also prevalent in the United States (King & et al., 2000). A
study sought to determine the under-diagnosis of at-risk people groups, such as northern
Europeans (Ivarsson & et al., 1999). This study showed that 5.3 out of 1000 adults in
Sweden have CD and many of these were unaware of their disease. Other previous
studies, which incorrectly diagnosed the disease, estimated that the prevalence was only 1
out of 1000 adult in Sweden. This emphasized the lack of awareness of CD. This study
can be generalized to many other populations because of the wide sample used (Ivarsson
& et al., 1999).
Mass Screenings
With the under-diagnosis of CD and the wide ranges of neurological disorders
without the classic gastrointestinal symptoms of CD, there is a potential need for mass
screening in the US for CD. However, as always, financing of such a procedure is in
question. Health care programs are trying to determine whether these screenings would
be cost-effective. One study attempted to measure the cost-effectiveness of mass
screening for CD (Shamir, Hernell, Leshno, 2006). It was found that 1 out of 200 people
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who were screened had CD. Taking into account the cost of treatment of CD (which is
merely switching a diet), the probability of complying with a gluten-free diet, and the
mortality rate of those with CD who go untreated, it was found that any screening
approach resulted in approximately $44,941 for the insurance companies for every year
of life gained to projected mortality rate. This study used a standardized mortality ratio
(SMR) (Shamir & et al., 2006). The ratio is found by dividing the observed deaths by the
expected deaths (Lilienfeld & Stolley, 1994). If the SMR is greater than 100, the
mortality rate is greater in that group of people. In those with undiagnosed CD, the
projected SMR was 150 or higher (Shamir & et al., 2006). In those who are diagnosed
with CD and adhere to a gluten-free lifestyle, the SMR was projected at even less than
100. This drop in mortality rate, paired with a monetary savings for every year of life
saved, helps to prove a benefit to screening for CD (Shamir & et al., 2006).
In Italy, mass screenings are much more common than in the United States
(D'Archivio & et al., 2004). A study in Italy, which tested 3188 school children for CD,
confirmed 33 positive for the disease (Tommasini & et al., 2003). The overall cost of the
mass-screening project was 46,000 Euros. Since 33 children were diagnosed, it is the
equivalent of 1,400 Euros per case diagnosed in cost (this includes the screening costs of
those without a diagnosis). The cost of a delayed or complicated diagnosis later in life
for a person with CD was found to be 8,700 Euros. This is an average of 7,300 Euros in
savings. Since the Italian government pays for the health care of its citizen, providing
screenings dramatically saves government spending. The study also found that 18 of the
33 children who were diagnosed with the disease had symptoms that were not
gastrointestinal. There were 21 children who had no symptoms at all. There were three
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who had atopic dermatitis and recurrent arthralgia, and two who had chronic fatigue and
anemia. This further shows the necessity to mass screen due to the variety of symptoms.
All 33 of these children felt significantly better after adhering to a gluten-free diet
(Tommasini & et al., 2003).
Italian physicians and researchers have been making great strides in early
diagnosis of patients and knowledge about CD. There has been an increase in the
diagnosis of patients who present with symptoms that are silent or non-gastrointestinal in
Italy since they have started doing mass screenings throughout the country (D'Archivio &
et al., 2004). This has allowed the patients to be diagnosed early in life, which lowers
morbidity rates in CD populations.
Conclusion
There have been new strides in the medical research community to seek out the
relationship between CD and neurological symptoms. The high prevalence of CD and
especially atypical CD in America today requires a more aggressive approach to achieve
diagnosis (Zipser & et al., 2005). Physicians and the general public need to be more
aware of the disease and the vast array of symptoms that present (Zipser & et al., 2005).
Mass screenings should be considered for implementation in high-risk people groups
(Shamir & et al., 2006). The more health care professionals and the general public know
about CD and how it affects health, especially in relation to health of the neurological
system, the greater the general public’s health will be.
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